

Special Issue

Molecular Pharming for Cancer Vaccines and Treatment

Message from the Guest Editors

Dear colleagues, This special issue of 'Vaccines' invites original research articles and reviews concerning the current state of the art of plant-derived technologies to preclude or treat cancers. This issue addresses plant-based production systems that preclude solid tumors, lymphomas and infection by oncogenic viruses along with plant-based cancer immunotherapy (monoclonal antibodies) for use in developing countries. Also addressed by this current issue are plant-derived pharmaceuticals that have been developed to fight cancer. The recent discovery of plant virus nanoparticles (VNPs) that target and penetrate solid tumors is particularly exciting. Plant viral nanoparticles can be produced in a facile manner with drugs functionalized to their surfaces, enabling them to easily home in and block tumor progression.

Guest Editors

Dr. Srividhya Venkataraman

Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada

Dr. Kathleen Hefferon

Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 1A1, Canada

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/109886

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).